Complex therapy of chronic bacterial prostatitis using the immunomodulatory drug sodium aminodihydrophthalazinedione

Shibaev A.N., Smernitsky A.M., Vitkina D.A.

1) Tver State Medical University, Ministry of Health of Russia, Tver, Russia; 2) Semashko Railway Clinical Hospital «RZD-Medicine», Moscow, Russia; 3) Vladimirsky Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russia

Introduction. Chronic bacterial prostatitis (CBP) is characterized by a recurrent course caused by pathogen persistence and impaired local immunity of the prostate. Aim. To assess the effectiveness of the use of sodium aminodihydrophthalazinedione in the complex therapy of chronic bacterial prostatitis. Materials and methods. The prospective comparative study included 60 men aged 21–50 years with CBP (NIH category II). Patients were randomized into two groups of 30: the comparison group received levofloxacin 500 mg/day for 28 days; the main group additionally received rectal sodium aminodihydrophthalazinedione. NIH-CPSI, IPSS, QoL, uroflowmetry, leukocyte and lecithin body counts in prostatic secretion, and bacteriological examination were assessed at baseline and on day 28, and the recurrence rate over 3 months. Results. By day 28, the main group showed a more pronounced decrease in the total NIH-CPSI score (8.1±2.1 vs 13.4±2.6; p<0.001), restoration of lecithin bodies (+65.1% vs +24.5%; p<0.05), normalization of uroflowmetry, and pathogen eradication in 86.7% vs 66.7% of patients (p<0.05). The 3-month recurrence rate decreased from 26.7 to 10.0% (p<0.05). No adverse events were registered. Discussion. The advantage of combinationtherapy is due to the combination of anti-inflammatory,immunomodulatory,antioxidantandregenerativeeffects of the drug,which is confirmed by the restoration of the secretoryfunction of the prostateepitheliumaccording to the dynamics of lecithingrains. Conclusion. The inclusion of sodium aminodihydrophthalazinedione in the combination therapy of CBP increases the clinical and microbiological efficacy of treatment and reduces the recurrence rate.

Keywords

About the Authors

Corresponding author: A.M. Smernitsky — Urologist, Clinical Hospital «RZD-Medicine» named after N.A. Semashko, Moscow, Russia; E-mail: andreysm2005@mail.ru

Similar Articles